|
gptkbp:instanceOf
|
gptkb:chemical_compound
anticonvulsant
|
|
gptkbp:affiliatedWith
|
hydantoin derivatives
|
|
gptkbp:approvedForMedicalUse
|
1938
|
|
gptkbp:ATCCode
|
gptkb:N03AB02
|
|
gptkbp:bioavailability
|
70-100%
|
|
gptkbp:brand
|
gptkb:Epanutin
gptkb:Dilantin
gptkb:Phenytek
|
|
gptkbp:CASNumber
|
57-41-0
|
|
gptkbp:cause
|
gptkb:toxic_epidermal_necrolysis
gptkb:Stevens-Johnson_syndrome
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
hypersensitivity to phenytoin
|
|
gptkbp:discoveredBy
|
gptkb:Heinrich_Biltz
|
|
gptkbp:discoveredIn
|
1908
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
JKMHFZQWWAIEOD-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C15H12N2O2
|
|
gptkbp:hasSMILES
|
C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
|
|
gptkbp:hasTherapeuticIndex
|
narrow
|
|
gptkbp:hasUNII
|
6158TKW0C5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
diphenylhydantoin
|
|
gptkbp:isOnWHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:IUPACName
|
5,5-diphenylimidazolidine-2,4-dione
|
|
gptkbp:KEGGID
|
D08445
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
|
|
gptkbp:meltingPoint
|
295°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
90-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
1707
1775
DB00252
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nystagmus
rash
ataxia
gingival hyperplasia
|
|
gptkbp:solubility
|
practically insoluble in water
|
|
gptkbp:synonym
|
gptkb:phenytoin
|
|
gptkbp:usedFor
|
epilepsy
seizure control
|
|
gptkbp:bfsParent
|
gptkb:phenytoin
|
|
gptkbp:bfsLayer
|
6
|